FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2332243386> ?p ?o ?g. }

• W2332243386 abstract "You have accessJournal of UrologyBladder Cancer: Basic Research & Pathophysiology II1 Apr 2016MP61-10 DNA METHYLATION INHIBITORS MAY REVERSE DRUG-RESISTANCE IN HUMAN BLADDER CANCER CELLS Naotaka Nishiyama, Stephanie Yi, Christopher E. Duymich, Siamak Daneshmand, Peter A. Jones, Hooman Djaladat, Naoya Masumori, and Gangning Liang Naotaka NishiyamaNaotaka Nishiyama More articles by this author , Stephanie YiStephanie Yi More articles by this author , Christopher E. DuymichChristopher E. Duymich More articles by this author , Siamak DaneshmandSiamak Daneshmand More articles by this author , Peter A. JonesPeter A. Jones More articles by this author , Hooman DjaladatHooman Djaladat More articles by this author , Naoya MasumoriNaoya Masumori More articles by this author , and Gangning LiangGangning Liang More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.884AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Aberrant DNA methylation is among common events during tumorigenesis. Although heritable, the dynamic nature and its potential reversibility with pharmacological interventions make it an interesting target for drugs. The aim of this study was to evaluate the chemotherapeutic re-sensitivity of cisplatin (CDDP) and gemcitabine (GEM) resistance in bladder cancer cell lines induced by the hypomethylating agent 5-aza-2-deoxycytidine (5-Aza-CdR). METHODS Six bladder cancer cell lines, T24, UMUC3, T24-RCDDP, UMUC3-RCDDP, T24-RGEM and UMUC3-RGEM cells were used. The drug resistance cell lines, T24-RCDDP/UMUC3-RCDDP and T24-RGEM/UMUC3-RGEM, were newly established at our laboratory. Cell lines were treated with 1µM 5-Aza-CdR for 24 hours on day 1, with CDDP (5µg/ml) and GEM (30nmol/ml) on day 2, or combinatorial treatment of 5-Aza-CdR (day 1) and either CDDP or GEM (day 2). The cell phonotypical alterations were monitored by cell double time, DNA methylation changes and gene expression changes. RESULTS We used the Illumina Infinium Human Methylation450 BeadArray to measure the DNA methylation changes at 482,421 CpGs, and found dramatic DNA methylation alterations between T24 and UMUC3 bladder cancer cell lines, as well as their drug-resistance counterparts (T24-RCDDP/T24-RGEM and UMUC3-RCDDP/UMUC3-RGEM). We identified DNA hypermethylation at 28,271 and 45,927 CpG sites in T24 and UMUC3 drug resistant cells, respectively. Furthermore, we identified DNA hypomethylation at 41,576 and 18,711 CpG sites in T24 and UMUC3 drug resistant cells, respectively. In addition, 5-Aza-CdR may re-sensitize CDDP-resistant cell lines, since the cell double time significantly increased from 70 (T24-RCDDP) or 86 (UMUC3-RCDDP) hours by CDDP alone to 495 (T24-RCDDP) or 721(UMUC3-RCDDP) hours after the combination treatments. However, it should be noted that the combination treatment of 5-Aza-CdR with GEM did not re-sensitize the chemotherapeutic effect on GEM-resistant cells. CONCLUSIONS Overall, our results indicate that alteration of DNA methylation may play an important role in drug-resistance, while DNA methylation re-programming may also sensitize the chemotherapeutic efficacy for drug resistance cells especially in metastatic urothelial carcinoma. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e806-e807 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Naotaka Nishiyama More articles by this author Stephanie Yi More articles by this author Christopher E. Duymich More articles by this author Siamak Daneshmand More articles by this author Peter A. Jones More articles by this author Hooman Djaladat More articles by this author Naoya Masumori More articles by this author Gangning Liang More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ..." @default.
• W2332243386 created "2016-06-24" @default.
• W2332243386 creator A5003368584 @default.
• W2332243386 creator A5017929805 @default.
• W2332243386 creator A5047940829 @default.
• W2332243386 creator A5060344480 @default.
• W2332243386 creator A5065222064 @default.
• W2332243386 creator A5076293102 @default.
• W2332243386 creator A5083918280 @default.
• W2332243386 creator A5088347458 @default.
• W2332243386 date "2016-04-01" @default.
• W2332243386 modified "2023-10-17" @default.
• W2332243386 title "MP61-10 DNA METHYLATION INHIBITORS MAY REVERSE DRUG-RESISTANCE IN HUMAN BLADDER CANCER CELLS" @default.
• W2332243386 doi "https://doi.org/10.1016/j.juro.2016.02.884" @default.
• W2332243386 hasPublicationYear "2016" @default.
• W2332243386 type Work @default.
• W2332243386 sameAs 2332243386 @default.
• W2332243386 citedByCount "0" @default.
• W2332243386 crossrefType "journal-article" @default.
• W2332243386 hasAuthorship W2332243386A5003368584 @default.
• W2332243386 hasAuthorship W2332243386A5017929805 @default.
• W2332243386 hasAuthorship W2332243386A5047940829 @default.
• W2332243386 hasAuthorship W2332243386A5060344480 @default.
• W2332243386 hasAuthorship W2332243386A5065222064 @default.
• W2332243386 hasAuthorship W2332243386A5076293102 @default.
• W2332243386 hasAuthorship W2332243386A5083918280 @default.
• W2332243386 hasAuthorship W2332243386A5088347458 @default.
• W2332243386 hasBestOaLocation W23322433861 @default.
• W2332243386 hasConcept C104317684 @default.
• W2332243386 hasConcept C114851261 @default.
• W2332243386 hasConcept C121608353 @default.
• W2332243386 hasConcept C126322002 @default.
• W2332243386 hasConcept C150194340 @default.
• W2332243386 hasConcept C190727270 @default.
• W2332243386 hasConcept C2776694085 @default.
• W2332243386 hasConcept C2777844706 @default.
• W2332243386 hasConcept C2778239845 @default.
• W2332243386 hasConcept C2780258809 @default.
• W2332243386 hasConcept C2780352672 @default.
• W2332243386 hasConcept C33288867 @default.
• W2332243386 hasConcept C41091548 @default.
• W2332243386 hasConcept C502942594 @default.
• W2332243386 hasConcept C54355233 @default.
• W2332243386 hasConcept C552990157 @default.
• W2332243386 hasConcept C555283112 @default.
• W2332243386 hasConcept C71924100 @default.
• W2332243386 hasConcept C81885089 @default.
• W2332243386 hasConcept C86803240 @default.
• W2332243386 hasConceptScore W2332243386C104317684 @default.
• W2332243386 hasConceptScore W2332243386C114851261 @default.
• W2332243386 hasConceptScore W2332243386C121608353 @default.
• W2332243386 hasConceptScore W2332243386C126322002 @default.
• W2332243386 hasConceptScore W2332243386C150194340 @default.
• W2332243386 hasConceptScore W2332243386C190727270 @default.
• W2332243386 hasConceptScore W2332243386C2776694085 @default.
• W2332243386 hasConceptScore W2332243386C2777844706 @default.
• W2332243386 hasConceptScore W2332243386C2778239845 @default.
• W2332243386 hasConceptScore W2332243386C2780258809 @default.
• W2332243386 hasConceptScore W2332243386C2780352672 @default.
• W2332243386 hasConceptScore W2332243386C33288867 @default.
• W2332243386 hasConceptScore W2332243386C41091548 @default.
• W2332243386 hasConceptScore W2332243386C502942594 @default.
• W2332243386 hasConceptScore W2332243386C54355233 @default.
• W2332243386 hasConceptScore W2332243386C552990157 @default.
• W2332243386 hasConceptScore W2332243386C555283112 @default.
• W2332243386 hasConceptScore W2332243386C71924100 @default.
• W2332243386 hasConceptScore W2332243386C81885089 @default.
• W2332243386 hasConceptScore W2332243386C86803240 @default.
• W2332243386 hasIssue "4S" @default.
• W2332243386 hasLocation W23322433861 @default.
• W2332243386 hasOpenAccess W2332243386 @default.
• W2332243386 hasPrimaryLocation W23322433861 @default.
• W2332243386 hasRelatedWork W2045656757 @default.
• W2332243386 hasRelatedWork W2167145211 @default.
• W2332243386 hasRelatedWork W2304569214 @default.
• W2332243386 hasRelatedWork W2364742912 @default.
• W2332243386 hasRelatedWork W2419052824 @default.
• W2332243386 hasRelatedWork W2512894035 @default.
• W2332243386 hasRelatedWork W2588398605 @default.
• W2332243386 hasRelatedWork W2745115887 @default.
• W2332243386 hasRelatedWork W3032749853 @default.
• W2332243386 hasRelatedWork W3210274727 @default.
• W2332243386 hasVolume "195" @default.
• W2332243386 isParatext "false" @default.
• W2332243386 isRetracted "false" @default.
• W2332243386 magId "2332243386" @default.
• W2332243386 workType "article" @default.